Chromosome 3q29 Microduplication Syndrome

👪

Inheritance

1

Autosomal dominant with reduced penetrance HP:0000006

The duplication behaves as a dominant but incompletely penetrant lesion. Both de novo and inherited cases occur, and inheritance from a similarly mildly affected parent is the common pattern rather than the exception.

Autosomal dominant inheritance Penetrance: INCOMPLETE Expressivity: VARIABLE

Show evidence (2 references)

PMID:38421086 SUPPORT Human Clinical

"Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype."

Establishes both that transmission is dominant and that the transmitting parent is typically affected only mildly, which is the substance of the reduced penetrance.

PMID:39739615 SUPPORT Human Clinical

"The syndrome is characterized by phenotypic polymorphism and reduced penetrance."

Reduced penetrance stated directly as a property of the syndrome.

?

Discussions and Knowledge Gaps

2

Does 3q29 duplication syndrome have a minimal critical region - BDH1, or DLG1 with BDH1 - or is no critical region supported by the data?

CONTROVERSY OPEN dup3q29_critical_region

Attached to

pathophysiology#Gain of Dosage of Synaptic and Metabolic Candidate Genes

Two lines of evidence point opposite ways and neither is obviously weaker. Successive small duplications have been used to shrink the region: 448 kb containing DLG1 and BDH1, then a second independent family with a 433 kb duplication of the same two genes, then five patients with 232-486 kb duplications used to argue for BDH1 alone. Against that, the largest published cohort - 31 families, nine of them with duplications under 1 Mb - looked at exactly this question in its own data and concluded there is no evidence for any critical region. The disagreement is not about a boundary, it is about the kind of disorder this is. A single-gene critical region would make it a BDH1 dosage disorder with a tractable mechanism. No critical region would make it a contiguous-gene effect in which the phenotype needs the interval rather than any member of it. The entry curates the candidate genes as candidates and the node's causal link to the clinical layer as INDIRECT_UNKNOWN_INTERMEDIATES for this reason. What would settle it is not another small duplication. Given the reduced penetrance and the frequency of second findings, small-duplication series are the wrong instrument - unaffected carriers of the small region are what the region-shrinking argument has to explain, and one of the two-gene families reports exactly that, an unaffected sibling and an unaffected transmitting mother with the same 432.8 kb duplication.

Show evidence (3 references)

PMID:39739615 SUPPORT Human Clinical

"For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."

The single-gene position.

PMID:38421086 REFUTE Human Clinical

"Besides, the study of small 3q29 duplications does not provide evidence for any critical region."

The no-critical-region position, from the larger cohort.

PMID:36691815 SUPPORT Human Clinical

"Here, we report on a family with two males with neurodevelopmental disorders and an unaffected sibling with a small 3q29 microduplication (432.8 Kb) inherited from an unaffected mother that involves only two genes: DGL1 and BDH1."

Cited for the fact that complicates both positions: in the very family used to refine the region, the same small duplication is carried by an unaffected sibling and an unaffected mother. The source prints "DGL1" for DLG1; the snippet reproduces it exactly.

Which 3q29 findings transfer between the deletion and the duplication, and which do not?

INTERPRETATION OPEN dup3q29_not_the_deletion

Attached to

disease#Chromosome 3q29 Microduplication Syndrome pathophysiology#Increased Dosage of the 3q29 Interval

The 3q29 literature is dominated by the deletion, and the most cited finding in it - the schizophrenia association - is a deletion finding. It is worth recording explicitly that it does not transfer, because the reciprocal relationship makes it easy to assume it does. The direct comparison gives three distinct patterns rather than one. Most phenotypes occur on both sides but significantly less often in duplication carriers. Overweight and weight deficit are mirrored, running opposite ways. And schizophrenia, generalised anxiety disorder and recurrent ear infections are reported as unique to deletion carriers. A counselling conversation that treats the duplication as a milder deletion gets the first pattern right and the other two wrong.

Show evidence (2 references)

PMID:39739615 SUPPORT Human Clinical

"Most of the phenotypes were observed in both groups but were significantly less common among individuals with 3q29 duplications."

The shared-but-attenuated pattern.

PMID:39739615 SUPPORT Human Clinical

"Schizophrenia, generalized anxiety disorder, and recurrent ear infections were unique phenotypes of patients carrying deletions."

The deletion-only phenotypes, and the direct source for not importing the schizophrenia association into this entry.

⚙

Pathophysiology

4

NAHR Between 3q29 Low-Copy Repeats

The 3q29 interval is flanked by almost identical low-copy repeats, and non-allelic homologous recombination between them generates a reciprocal deletion/duplication pair. Optical genome mapping across 18 probands localised the crossovers tightly: in 89% of them the breakpoints lay within paralogous copies of one 20 kb segment inside the segmental duplications. Unlike the 8p and 15q recurrent rearrangements, no parent-of-origin inversion polymorphism has been found at this locus.

Downstream

Increased Dosage of the 3q29 Interval

Show evidence (3 references)

PMID:39739615 SUPPORT Human Clinical

"which indicates that nonallelic homologous recombination is the most likely mechanism for rearrangement formation"

Names the mechanism directly. An earlier version of this item quoted the first half of the same sentence and stopped at "almost identical low", because the cached text carries a U+2010 HYPHEN inside "low-copy repeats" - so the truncated quote did not mention NAHR at all. This clause sits immediately after that character and verifies unchanged.

PMID:37165454 SUPPORT Human Clinical

"In 89% (16/18) of the probands, breakpoints were confined to paralogous copies of a 20-kbp segment within the 3q29 SDs."

Localises the recombination to a specific paralogous segment rather than to the segmental duplications generally.

PMID:37165454 SUPPORT Human Clinical

"Finally, we found no evidence of inversions in parent-of-origin chromosomes."

A negative result worth curating: the inversion-polymorphism model that explains other recurrent NAHR rearrangements was looked for here and not found.

Increased Dosage of the 3q29 Interval

The recurrent lesion carries 21 protein-coding genes at three copies rather than two. The functional consequence is presumed increased expression of dosage-sensitive genes rather than loss of any function, which is why the duplication phenotype is not simply a milder version of the deletion phenotype and why some features mirror rather than parallel it.

Downstream

Gain of Dosage of Synaptic and Metabolic Candidate Genes

Show evidence (2 references)

PMID:37165454 SUPPORT Human Clinical

"There are 21 protein-coding genes lost or gained as a result of such recurrent 1.6-Mbp deletions or duplications, respectively, in the 3q29 locus."

The gene content of the interval, stated for both directions of the rearrangement.

PMID:39739615 SUPPORT Human Clinical

"Mirrored phenotypes in patients with duplications and deletions included overweight and weight deficit."

Evidence that the two directions are not simply graded versions of one another: at least one trait runs opposite ways, which is what a dosage model predicts and a severity model does not.

Gain of Dosage of Synaptic and Metabolic Candidate Genes

Which gene or genes in the interval drive the phenotype is unresolved. The candidates repeatedly nominated are synaptic - DLG1, PAK2, FBXO45 - plus the mitochondrial ketone-body enzyme BDH1, and successive minimal-region analyses have converged on DLG1 with BDH1 and then on BDH1 alone. The largest cohort disputes that any critical region exists. This node therefore asserts the class of mechanism, not the gene.

DLG1 hgnc:2900 BDH1 hgnc:1027

synapse organization GO:0050808 ⚠ ABNORMAL

Downstream

Altered Neurodevelopment with Incomplete Penetrance

Abnormality of the Eye

Abnormal Heart Morphology

Abnormal Facial Shape

Show evidence (3 references)

PMID:29501613 SUPPORT Human Clinical

"Gene content analysis of the duplicated region suggests that gain-of-dosage of DLG1 and BDH1 may be a good candidate for the main clinical features of this syndrome."

The two-gene nomination, phrased by its own authors as a suggestion rather than a finding.

PMID:39739615 SUPPORT Human Clinical

"For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."

The single-gene refinement, and the phenotypes seen in those carriers.

PMID:38421086 REFUTE Human Clinical

"Besides, the study of small 3q29 duplications does not provide evidence for any critical region."

Recorded as REFUTE against the claim that a critical region has been established. It is the counter-position in discussions#dup3q29_critical_region and is curated alongside the claim rather than after it.

Altered Neurodevelopment with Incomplete Penetrance

The clinical layer. Isolated 3q29 duplications produce mainly mild neurodevelopmental impairment - a high rate of learning disability against a low proportion with frank intellectual disability - and the same duplication is carried by mildly affected or unaffected relatives. Additional genetic findings were identified in a substantial minority of patients, which is why the cohort authors advise looking further when the presentation is severe.

Downstream

Delayed Speech and Language Development

Specific Learning Disability

Global Developmental Delay

Intellectual Disability

Autism

Seizure

Microcephaly

Macrocephaly

Obesity

Show evidence (2 references)

PMID:38421086 SUPPORT Human Clinical

"Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."

The severity calibration, and specifically the pattern of learning disability predominating over intellectual disability, which distinguishes this from the deletion.

PMID:38421086 SUPPORT Human Clinical

"Additional genetic findings that may be involved in the phenotype were identified in 11 patients."

Quantifies how often something other than the duplication may be doing the work, which is what makes attribution to the duplication provisional in an individual patient.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

12

Cardiovascular 1

Abnormal Heart Morphology OCCASIONAL HP:0001627

Show evidence (1 reference)

PMID:39739615 SUPPORT Human Clinical

"For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."

Heart defects among the features of the smallest-duplication carriers, which is the most specific genotype-phenotype statement available for this feature.

Eye 1

Abnormality of the Eye OCCASIONAL HP:0000478

Bound to the general "Abnormality of the eye" deliberately. No cited source names a specific ocular structure or lesion, so a narrower HP term would assert a finding the literature does not report.

Show evidence (1 reference)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

Ocular abnormalities within the reported feature set.

Head and Neck 3

Microcephaly FREQUENT HP:0000252

Show evidence (1 reference)

PMID:29501613 SUPPORT Human Clinical

"microcephaly that is present in about the half of the reported patients"

The frequency estimate that this grading rests on.

Macrocephaly OCCASIONAL HP:0000256

Show evidence (1 reference)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

"micro/macrocephaly" in the literature-wide feature list, which is the source for both head-size phenotypes in this entry.

Abnormal Facial Shape FREQUENT HP:0001999

Show evidence (1 reference)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

Distinctive facial features within the reported feature set.

Nervous System 6

Delayed Speech and Language Development FREQUENT HP:0000750

Show evidence (2 references)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

The literature-wide feature list. Cited once here and reused for the other features it names rather than being paraphrased per phenotype.

PMID:29501613 SUPPORT Human Clinical

"Heterogeneous clinical and neuropsychological features, such as intellectual disability, developmental and language delay, hypotonia, and, to a lesser extent, microcephaly that is present in about the half of the reported patients, characterize the 3q29 microduplication syndrome with usually a..."

Independent statement of the feature set, and the source for the microcephaly frequency and the milder-than-deletion comparison.

Specific Learning Disability FREQUENT HP:0001328

Show evidence (1 reference)

PMID:38421086 SUPPORT Human Clinical

"Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."

Both the presence of learning disability and its dominance over intellectual disability in the same sentence.

Global Developmental Delay FREQUENT HP:0001263

Show evidence (1 reference)

PMID:29501613 SUPPORT Human Clinical

"Heterogeneous clinical and neuropsychological features, such as intellectual disability, developmental and language delay, hypotonia, and, to a lesser extent, microcephaly that is present in about the half of the reported patients, characterize the 3q29 microduplication syndrome with usually a..."

Developmental delay within the syndrome's characteristic feature set.

Intellectual Disability OCCASIONAL HP:0001249

Severity: MILD

Show evidence (2 references)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

Intellectual disability within the reported feature set.

PMID:38421086 SUPPORT Human Clinical

"Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."

The basis for grading this OCCASIONAL rather than FREQUENT: the same cohort that reports it also reports it as the minority cognitive outcome.

Autism OCCASIONAL HP:0000717

Show evidence (1 reference)

PMID:39739615 SUPPORT Human Clinical

"For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."

Autism spectrum disorder among the features of the smallest-duplication carriers, which is the most specific genotype-phenotype statement available for this feature.

Seizure OCCASIONAL HP:0001250

Show evidence (1 reference)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

Epilepsy within the reported feature set.

Growth 1

Obesity OCCASIONAL HP:0001513

Show evidence (2 references)

PMID:33039685 SUPPORT Human Clinical

"clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"

Generalised obesity within the reported feature set.

PMID:39739615 SUPPORT Human Clinical

"Mirrored phenotypes in patients with duplications and deletions included overweight and weight deficit."

The mirroring, which is why weight is curated here as a dosage effect.

🧬

Genetic Associations

1

3q29 recurrent duplication

relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (2 references)

PMID:37165454 SUPPORT Human Clinical

"There are 21 protein-coding genes lost or gained as a result of such recurrent 1.6-Mbp deletions or duplications, respectively, in the 3q29 locus."

Size and gene content of the recurrent lesion.

PMID:38421086 SUPPORT Human Clinical

"We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb)."

The size distribution in the largest cohort, which is what makes "the recurrent 1.6 Mb duplication" only part of what is seen in practice.

💊

Medical Actions

1

Genetic Counselling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Platform: Other

The intervention this entry's whole argument bears on. Three facts have to be conveyed together and each one on its own misleads: penetrance is reduced and most duplications are inherited from a mildly affected or unaffected parent; additional contributory genetic findings are common enough that a severe presentation should prompt further testing rather than attribution to the duplication; and the schizophrenia association that dominates the 3q29 literature belongs to the reciprocal deletion, not to this.

Show evidence (2 references)

PMID:38421086 SUPPORT Human Clinical

"Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype."

The inheritance pattern a counselling conversation has to start from, and the reason parental testing changes the recurrence discussion.

PMID:39739615 SUPPORT Human Clinical

"Schizophrenia, generalized anxiety disorder, and recurrent ear infections were unique phenotypes of patients carrying deletions."

The deletion-only phenotypes, cited here because importing them into a duplication counselling conversation is the specific error this record exists to prevent.

🔬

Diagnosis

2

Chromosomal microarray analysis

The duplication is submicroscopic, so karyotype is normal and detection is by microarray.

Show evidence (1 reference)

PMID:38421086 SUPPORT Human Clinical

"We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb)."

CMA as the ascertainment method for the whole cohort.

Further genetic analysis when the presentation is severe

A severe or syndromic presentation in a 3q29 duplication carrier should not be attributed to the duplication without looking further, because additional contributory findings are common and the duplication alone predicts mild disease.

Show evidence (1 reference)

PMID:38421086 SUPPORT Human Clinical

"Our data suggest that the overlapping and recurrent 3q29 duplications seem to lead to mild NDD and that a severe or syndromic clinical presentation should warrant further genetic analyses."

The authors' explicit diagnostic recommendation, which is the actionable output of the reduced-penetrance finding.

📊

Prevalence

1

Patients referred with a neurodevelopmental phenotype

Point Prevalence 20.0 per 100,000 1–9 per 10,000

1 in 5000 among patients with a neurodevelopmental phenotype. This is a rate within a referred population, not a population prevalence, and is recorded as such. The band is BAND_1_5_PER_10000, which covers 10-99 per 100,000 and so contains 20.0. An earlier version of this record paired the same rate with BAND_1_9_PER_100000, one tier too low; nothing cross-checks prevalence_class against rate_per_100000, so that had to be caught by reading.

Show evidence (1 reference)

PMID:39739615 SUPPORT Human Clinical

"Chromosome 3q29 duplication syndrome is a rare chromosomal disorder with a frequency of 1:5000 in patients with a neurodevelopmental phenotype."

The referred-cohort frequency, with its denominator stated in the same sentence.

{ }

Source YAML

click to show

name: Chromosome 3q29 Microduplication Syndrome
category: Chromosomal
creation_date: "2026-09-03T19:00:00Z"
synonyms:
- 3q29 microduplication syndrome
- 3q29 duplication syndrome
- dup3q29S
- trisomy 3q29
- dup(3)(q29)
description: >-
  Chromosome 3q29 microduplication syndrome is the copy-number *gain* of the recurrent ~1.6 Mb
  interval at 3q29, the reciprocal of the much better characterised 3q29 microdeletion. It
  presents as a variable and generally mild neurodevelopmental disorder: speech and language
  delay, learning disability, and a scatter of accessory features that includes microcephaly
  or macrocephaly, ocular and cardiac anomalies, obesity and dysmorphism.

  The mechanism of formation is settled and is the same one that produces the deletion. The
  interval is flanked by near-identical low-copy repeats, and non-allelic homologous
  recombination between them yields a reciprocal pair. Optical genome mapping across probands
  narrowed the crossovers further: in 89% of probands the breakpoints fell inside paralogous
  copies of a single 20 kb segment within the 3q29 segmental duplications.

  Everything downstream of that is less settled, and this entry is written to keep the two
  apart. Two claims in particular are curated as contested rather than as facts.

  The first is the minimal critical region. Successive reports have shrunk it from the full
  interval to DLG1 plus BDH1 (448 kb, then 433 kb in an independent family) and then to BDH1
  alone in patients with duplications of 232-486 kb. Against that, the largest cohort to date
  looked at its own small duplications and concluded they provide no evidence for any critical
  region at all. Both are curated, as a CONTROVERSY, because the disagreement is not a detail:
  a single-gene critical region would make this a BDH1 dosage disorder, and no critical region
  would make it a contiguous-gene effect.

  The second is what the duplication is *for* a carrier. Most 3q29 duplications are inherited
  from a parent with a similar mild phenotype, penetrance is reduced, and additional genetic
  findings that might themselves explain the presentation were identified in 11 of 46 patients
  in one series. The cohort's own conclusion is the practical one and is curated here: a
  severe or syndromic presentation in a 3q29 duplication carrier should prompt further genetic
  analysis rather than being attributed to the duplication.

  The contrast with the reciprocal deletion is the other thing worth curating explicitly,
  because the two are easy to conflate and the asymmetry matters for counselling. Most
  phenotypes occur on both sides but are significantly less common in duplication carriers.
  Overweight and weight deficit are mirrored between them. And schizophrenia, generalised
  anxiety disorder and recurrent ear infections are phenotypes of deletion carriers only - so
  the schizophrenia association that dominates the 3q29 literature does not transfer to this
  entry.
disease_term:
  preferred_term: chromosome 3q29 microduplication syndrome
  term:
    id: MONDO:0012761
    label: chromosome 3q29 microduplication syndrome
parents:
- Chromosomal Duplication Syndrome
inheritance:
- name: Autosomal dominant with reduced penetrance
  description: >-
    The duplication behaves as a dominant but incompletely penetrant lesion. Both de novo and
    inherited cases occur, and inheritance from a similarly mildly affected parent is the
    common pattern rather than the exception.
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  penetrance: INCOMPLETE
  expressivity: VARIABLE
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype."
    explanation: >-
      Establishes both that transmission is dominant and that the transmitting parent is
      typically affected only mildly, which is the substance of the reduced penetrance.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The syndrome is characterized by phenotypic polymorphism and reduced penetrance."
    explanation: Reduced penetrance stated directly as a property of the syndrome.
prevalence:
- population: Patients referred with a neurodevelopmental phenotype
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_5_PER_10000
  rate_per_100000: 20.0
  notes: >-
    1 in 5000 among patients with a neurodevelopmental phenotype. This is a rate within a
    referred population, not a population prevalence, and is recorded as such.

    The band is BAND_1_5_PER_10000, which covers 10-99 per 100,000 and so contains 20.0. An
    earlier version of this record paired the same rate with BAND_1_9_PER_100000, one tier too
    low; nothing cross-checks prevalence_class against rate_per_100000, so that had to be caught
    by reading.
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Chromosome 3q29 duplication syndrome is a rare chromosomal disorder with a frequency of 1:5000 in patients with a neurodevelopmental phenotype."
    explanation: The referred-cohort frequency, with its denominator stated in the same sentence.
pathophysiology:
- name: NAHR Between 3q29 Low-Copy Repeats
  biological_scale: MOLECULAR
  description: >-
    The 3q29 interval is flanked by almost identical low-copy repeats, and non-allelic
    homologous recombination between them generates a reciprocal deletion/duplication pair.
    Optical genome mapping across 18 probands localised the crossovers tightly: in 89% of them
    the breakpoints lay within paralogous copies of one 20 kb segment inside the segmental
    duplications. Unlike the 8p and 15q recurrent rearrangements, no parent-of-origin inversion
    polymorphism has been found at this locus.
  downstream:
  - target: Increased Dosage of the 3q29 Interval
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "which indicates that nonallelic homologous recombination is the most likely mechanism for rearrangement formation"
    explanation: >-
      Names the mechanism directly. An earlier version of this item quoted the first half of the
      same sentence and stopped at "almost identical low", because the cached text carries a
      U+2010 HYPHEN inside "low-copy repeats" - so the truncated quote did not mention NAHR at
      all. This clause sits immediately after that character and verifies unchanged.
  - reference: PMID:37165454
    reference_title: "High level of complexity and global diversity of the 3q29 locus revealed by optical mapping and long-read sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 89% (16/18) of the probands, breakpoints were confined to paralogous copies of a 20-kbp segment within the 3q29 SDs."
    explanation: >-
      Localises the recombination to a specific paralogous segment rather than to the
      segmental duplications generally.
  - reference: PMID:37165454
    reference_title: "High level of complexity and global diversity of the 3q29 locus revealed by optical mapping and long-read sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Finally, we found no evidence of inversions in parent-of-origin chromosomes."
    explanation: >-
      A negative result worth curating: the inversion-polymorphism model that explains other
      recurrent NAHR rearrangements was looked for here and not found.
- name: Increased Dosage of the 3q29 Interval
  biological_scale: MOLECULAR
  description: >-
    The recurrent lesion carries 21 protein-coding genes at three copies rather than two. The
    functional consequence is presumed increased expression of dosage-sensitive genes rather
    than loss of any function, which is why the duplication phenotype is not simply a milder
    version of the deletion phenotype and why some features mirror rather than parallel it.
  downstream:
  - target: Gain of Dosage of Synaptic and Metabolic Candidate Genes
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:37165454
    reference_title: "High level of complexity and global diversity of the 3q29 locus revealed by optical mapping and long-read sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are 21 protein-coding genes lost or gained as a result of such recurrent 1.6-Mbp deletions or duplications, respectively, in the 3q29 locus."
    explanation: The gene content of the interval, stated for both directions of the rearrangement.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mirrored phenotypes in patients with duplications and deletions included overweight and weight deficit."
    explanation: >-
      Evidence that the two directions are not simply graded versions of one another: at least
      one trait runs opposite ways, which is what a dosage model predicts and a severity model
      does not.
- name: Gain of Dosage of Synaptic and Metabolic Candidate Genes
  biological_scale: CELLULAR
  description: >-
    Which gene or genes in the interval drive the phenotype is unresolved. The candidates
    repeatedly nominated are synaptic - DLG1, PAK2, FBXO45 - plus the mitochondrial ketone-body
    enzyme BDH1, and successive minimal-region analyses have converged on DLG1 with BDH1 and
    then on BDH1 alone. The largest cohort disputes that any critical region exists. This node
    therefore asserts the class of mechanism, not the gene.
  genes:
  - preferred_term: DLG1
    term:
      id: hgnc:2900
      label: DLG1
  - preferred_term: BDH1
    term:
      id: hgnc:1027
      label: BDH1
  biological_processes:
  - preferred_term: synapse organization
    modifier: ABNORMAL
    term:
      id: GO:0050808
      label: synapse organization
  downstream:
  - target: Altered Neurodevelopment with Incomplete Penetrance
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Abnormality of the Eye
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Abnormal Heart Morphology
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Abnormal Facial Shape
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:29501613
    reference_title: "3q29 microduplication syndrome: Description of two new cases and delineation of the minimal critical region."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Gene content analysis of the duplicated region suggests that gain-of-dosage of DLG1 and BDH1 may be a good candidate for the main clinical features of this syndrome."
    explanation: >-
      The two-gene nomination, phrased by its own authors as a suggestion rather than a
      finding.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."
    explanation: The single-gene refinement, and the phenotypes seen in those carriers.
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides, the study of small 3q29 duplications does not provide evidence for any critical region."
    explanation: >-
      Recorded as REFUTE against the claim that a critical region has been established. It is
      the counter-position in discussions#dup3q29_critical_region and is curated alongside the
      claim rather than after it.
  notes: >-
    The genes listed here are the candidates the literature nominates, not established drivers.
    No functional experiment in any cited source tests dosage of DLG1 or BDH1 against the
    phenotype; the nominations rest on interval overlap.
- name: Altered Neurodevelopment with Incomplete Penetrance
  biological_scale: ORGANISM
  description: >-
    The clinical layer. Isolated 3q29 duplications produce mainly mild neurodevelopmental
    impairment - a high rate of learning disability against a low proportion with frank
    intellectual disability - and the same duplication is carried by mildly affected or
    unaffected relatives. Additional genetic findings were identified in a substantial minority
    of patients, which is why the cohort authors advise looking further when the presentation
    is severe.
  downstream:
  - target: Delayed Speech and Language Development
    causal_link_type: DIRECT
  - target: Specific Learning Disability
    causal_link_type: DIRECT
  - target: Global Developmental Delay
    causal_link_type: DIRECT
  - target: Intellectual Disability
    causal_link_type: DIRECT
  - target: Autism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Macrocephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Obesity
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."
    explanation: >-
      The severity calibration, and specifically the pattern of learning disability
      predominating over intellectual disability, which distinguishes this from the deletion.
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Additional genetic findings that may be involved in the phenotype were identified in 11 patients."
    explanation: >-
      Quantifies how often something other than the duplication may be doing the work, which is
      what makes attribution to the duplication provisional in an individual patient.
phenotypes:
- name: Delayed Speech and Language Development
  category: Neurodevelopmental
  description: >-
    The most consistently reported feature, present across cohorts and case series.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Delayed speech and language development
    term:
      id: HP:0000750
      label: Delayed speech and language development
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: >-
      The literature-wide feature list. Cited once here and reused for the other features it
      names rather than being paraphrased per phenotype.
  - reference: PMID:29501613
    reference_title: "3q29 microduplication syndrome: Description of two new cases and delineation of the minimal critical region."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterogeneous clinical and neuropsychological features, such as intellectual disability, developmental and language delay, hypotonia, and, to a lesser extent, microcephaly that is present in about the half of the reported patients, characterize the 3q29 microduplication syndrome with usually a milder phenotype compared with the corresponding 3q29 microdeletion syndrome."
    explanation: >-
      Independent statement of the feature set, and the source for the microcephaly frequency
      and the milder-than-deletion comparison.
- name: Specific Learning Disability
  category: Neurodevelopmental
  description: >-
    Learning disability rather than intellectual disability is the characteristic cognitive
    outcome in isolated duplications, and the ratio between the two is the clearest single
    difference from the reciprocal deletion.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Specific learning disability
    term:
      id: HP:0001328
      label: Specific learning disability
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."
    explanation: >-
      Both the presence of learning disability and its dominance over intellectual disability
      in the same sentence.
- name: Global Developmental Delay
  category: Neurodevelopmental
  description: Developmental delay across domains, reported in infancy and childhood.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:29501613
    reference_title: "3q29 microduplication syndrome: Description of two new cases and delineation of the minimal critical region."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterogeneous clinical and neuropsychological features, such as intellectual disability, developmental and language delay, hypotonia, and, to a lesser extent, microcephaly that is present in about the half of the reported patients, characterize the 3q29 microduplication syndrome with usually a milder phenotype compared with the corresponding 3q29 microdeletion syndrome."
    explanation: Developmental delay within the syndrome's characteristic feature set.
- name: Intellectual Disability
  category: Neurodevelopmental
  description: >-
    Present but distinctly less common than learning disability in isolated duplications, and
    less common than in deletion carriers.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
    severity: MILD
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: Intellectual disability within the reported feature set.
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Focusing on apparently isolated 3q29 duplications, patients present mainly mild NDD as suggested by a high rate of learning disabilities in contrast to a low proportion of patients with intellectual disabilities."
    explanation: >-
      The basis for grading this OCCASIONAL rather than FREQUENT: the same cohort that reports
      it also reports it as the minority cognitive outcome.
- name: Microcephaly
  category: Craniofacial
  description: >-
    Reported in about half of published patients. Macrocephaly is also described, so head size
    varies in both directions rather than in one.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:29501613
    reference_title: "3q29 microduplication syndrome: Description of two new cases and delineation of the minimal critical region."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "microcephaly that is present in about the half of the reported patients"
    explanation: The frequency estimate that this grading rests on.
- name: Autism
  category: Behavioral
  description: >-
    Autistic features are reported across series, and were among the phenotypes seen in the
    patients whose duplication was confined to BDH1.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Autism
    term:
      id: HP:0000717
      label: Autism
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."
    explanation: >-
      Autism spectrum disorder among the features of the smallest-duplication carriers, which
      is the most specific genotype-phenotype statement available for this feature.
- name: Seizure
  category: Neurological
  description: Epilepsy occurs in a subset of carriers.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: Epilepsy within the reported feature set.
- name: Macrocephaly
  category: Craniofacial
  description: >-
    Head size varies in both directions in this syndrome. Macrocephaly is reported alongside
    microcephaly across the literature, which is one of the ways the duplication phenotype is
    not simply a graded version of the deletion's.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Macrocephaly
    term:
      id: HP:0000256
      label: Macrocephaly
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: >-
      "micro/macrocephaly" in the literature-wide feature list, which is the source for both
      head-size phenotypes in this entry.
- name: Abnormality of the Eye
  category: Ophthalmological
  description: >-
    Ocular abnormalities are part of the reported feature set. The cited sources name them as a
    category without specifying which structures, so the binding stays at that level.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ocular abnormalities
    term:
      id: HP:0000478
      label: Abnormality of the eye
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: Ocular abnormalities within the reported feature set.
  notes: >-
    Bound to the general "Abnormality of the eye" deliberately. No cited source names a specific
    ocular structure or lesion, so a narrower HP term would assert a finding the literature does
    not report.
- name: Abnormal Facial Shape
  category: Craniofacial
  description: >-
    Distinctive facial features are reported across series. As with the ocular findings, the
    sources describe a gestalt rather than named components.
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Distinctive facial features
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: Distinctive facial features within the reported feature set.
- name: Abnormal Heart Morphology
  category: Cardiovascular
  description: >-
    Congenital heart defects are reported in duplication carriers, including in the patients
    whose duplication was confined to BDH1.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Congenital heart defect
    term:
      id: HP:0001627
      label: Abnormal heart morphology
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."
    explanation: >-
      Heart defects among the features of the smallest-duplication carriers, which is the most
      specific genotype-phenotype statement available for this feature.
- name: Obesity
  category: Metabolic
  description: >-
    Generalised obesity is reported in the syndrome, and is one of the traits that runs in
    opposite directions between duplication and deletion carriers rather than simply being
    milder in one.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Obesity
    term:
      id: HP:0001513
      label: Obesity
  evidence:
  - reference: PMID:33039685
    reference_title: "3q29 microduplication syndrome: Clinical and molecular description of eleven new cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies"
    explanation: Generalised obesity within the reported feature set.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Mirrored phenotypes in patients with duplications and deletions included overweight and weight deficit."
    explanation: The mirroring, which is why weight is curated here as a dosage effect.
genetic:
- name: 3q29 recurrent duplication
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  features: >-
    A recurrent interstitial copy-number gain of ~1.6 Mb at 3q29 containing 21 protein-coding
    genes, generated by NAHR between the flanking low-copy repeats. Smaller overlapping
    duplications down to about 232 kb have been reported, and they are what the debate over a
    minimal critical region turns on.
  evidence:
  - reference: PMID:37165454
    reference_title: "High level of complexity and global diversity of the 3q29 locus revealed by optical mapping and long-read sequencing."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There are 21 protein-coding genes lost or gained as a result of such recurrent 1.6-Mbp deletions or duplications, respectively, in the 3q29 locus."
    explanation: Size and gene content of the recurrent lesion.
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb)."
    explanation: >-
      The size distribution in the largest cohort, which is what makes "the recurrent 1.6 Mb
      duplication" only part of what is seen in practice.
diagnosis:
- name: Chromosomal microarray analysis
  description: >-
    The duplication is submicroscopic, so karyotype is normal and detection is by microarray.
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We here report a French cohort of 31 families with a 3q29 duplication identified by chromosomal microarray analysis (CMA), including 14 recurrent 1.6 Mb duplications, eight overlapping duplications (>1 Mb), and nine small duplications (<1 Mb)."
    explanation: CMA as the ascertainment method for the whole cohort.
- name: Further genetic analysis when the presentation is severe
  description: >-
    A severe or syndromic presentation in a 3q29 duplication carrier should not be attributed
    to the duplication without looking further, because additional contributory findings are
    common and the duplication alone predicts mild disease.
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our data suggest that the overlapping and recurrent 3q29 duplications seem to lead to mild NDD and that a severe or syndromic clinical presentation should warrant further genetic analyses."
    explanation: >-
      The authors' explicit diagnostic recommendation, which is the actionable output of the
      reduced-penetrance finding.
treatments:
- name: Genetic Counselling
  therapeutic_modality: OTHER
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    The intervention this entry's whole argument bears on. Three facts have to be conveyed
    together and each one on its own misleads: penetrance is reduced and most duplications are
    inherited from a mildly affected or unaffected parent; additional contributory genetic
    findings are common enough that a severe presentation should prompt further testing rather
    than attribution to the duplication; and the schizophrenia association that dominates the
    3q29 literature belongs to the reciprocal deletion, not to this.
  evidence:
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Although some are de novo, most of the 3q29 duplications are inherited from a parent with a similar mild phenotype."
    explanation: >-
      The inheritance pattern a counselling conversation has to start from, and the reason
      parental testing changes the recurrence discussion.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schizophrenia, generalized anxiety disorder, and recurrent ear infections were unique phenotypes of patients carrying deletions."
    explanation: >-
      The deletion-only phenotypes, cited here because importing them into a duplication
      counselling conversation is the specific error this record exists to prevent.
  notes: >-
    No study measures counselling outcomes in 3q29 duplication. The evidence items attached here
    substantiate the facts to be conveyed, not the effectiveness of conveying them.
discussions:
- discussion_id: dup3q29_critical_region
  kind: CONTROVERSY
  status: OPEN
  prompt: >-
    Does 3q29 duplication syndrome have a minimal critical region - BDH1, or DLG1 with BDH1 -
    or is no critical region supported by the data?
  attaches_to:
  - pathophysiology#Gain of Dosage of Synaptic and Metabolic Candidate Genes
  rationale: >-
    Two lines of evidence point opposite ways and neither is obviously weaker. Successive small
    duplications have been used to shrink the region: 448 kb containing DLG1 and BDH1, then a
    second independent family with a 433 kb duplication of the same two genes, then five
    patients with 232-486 kb duplications used to argue for BDH1 alone. Against that, the
    largest published cohort - 31 families, nine of them with duplications under 1 Mb - looked
    at exactly this question in its own data and concluded there is no evidence for any
    critical region.

    The disagreement is not about a boundary, it is about the kind of disorder this is. A
    single-gene critical region would make it a BDH1 dosage disorder with a tractable
    mechanism. No critical region would make it a contiguous-gene effect in which the
    phenotype needs the interval rather than any member of it. The entry curates the candidate
    genes as candidates and the node's causal link to the clinical layer as
    INDIRECT_UNKNOWN_INTERMEDIATES for this reason.

    What would settle it is not another small duplication. Given the reduced penetrance and the
    frequency of second findings, small-duplication series are the wrong instrument - unaffected
    carriers of the small region are what the region-shrinking argument has to explain, and one
    of the two-gene families reports exactly that, an unaffected sibling and an unaffected
    transmitting mother with the same 432.8 kb duplication.
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "For the first time, we delineated and described the smallest minimal critical region, including the single BDH1 gene; in our patients, this region was associated with ASD, heart defects, biliary tract dysfunction, and obesity."
    explanation: The single-gene position.
  - reference: PMID:38421086
    reference_title: "3q29 duplications: A cohort of 46 patients and a literature review."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "Besides, the study of small 3q29 duplications does not provide evidence for any critical region."
    explanation: The no-critical-region position, from the larger cohort.
  - reference: PMID:36691815
    reference_title: "3q29 microduplication syndrome: New evidence for the refinement of the critical region."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here, we report on a family with two males with neurodevelopmental disorders and an unaffected sibling with a small 3q29 microduplication (432.8 Kb) inherited from an unaffected mother that involves only two genes: DGL1 and BDH1."
    explanation: >-
      Cited for the fact that complicates both positions: in the very family used to refine the
      region, the same small duplication is carried by an unaffected sibling and an unaffected
      mother. The source prints "DGL1" for DLG1; the snippet reproduces it exactly.
- discussion_id: dup3q29_not_the_deletion
  kind: INTERPRETATION
  status: OPEN
  prompt: >-
    Which 3q29 findings transfer between the deletion and the duplication, and which do not?
  attaches_to:
  - disease#Chromosome 3q29 Microduplication Syndrome
  - pathophysiology#Increased Dosage of the 3q29 Interval
  rationale: >-
    The 3q29 literature is dominated by the deletion, and the most cited finding in it - the
    schizophrenia association - is a deletion finding. It is worth recording explicitly that it
    does not transfer, because the reciprocal relationship makes it easy to assume it does.

    The direct comparison gives three distinct patterns rather than one. Most phenotypes occur
    on both sides but significantly less often in duplication carriers. Overweight and weight
    deficit are mirrored, running opposite ways. And schizophrenia, generalised anxiety
    disorder and recurrent ear infections are reported as unique to deletion carriers. A
    counselling conversation that treats the duplication as a milder deletion gets the first
    pattern right and the other two wrong.
  evidence:
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Most of the phenotypes were observed in both groups but were significantly less common among individuals with 3q29 duplications."
    explanation: The shared-but-attenuated pattern.
  - reference: PMID:39739615
    reference_title: "Delineation of the Genetic Architecture and Clinical Polymorphism of 3q29 Duplication Syndrome: A Review of the Literature and a Report of Two Novel Patients With Single-Gene BDH1 Duplications."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Schizophrenia, generalized anxiety disorder, and recurrent ear infections were unique phenotypes of patients carrying deletions."
    explanation: >-
      The deletion-only phenotypes, and the direct source for not importing the schizophrenia
      association into this entry.
notes: >-
  Relationship to kb/disorders/Chromosome_3q29_Microdeletion_Syndrome. The two are reciprocal
  products of one NAHR event and are separate entries because they are separate diseases, not
  two severities of one. This entry does not restate the deletion's pathophysiology; where the
  comparison is informative it is curated as evidence, in
  discussions#dup3q29_not_the_deletion.

  A late-onset presentation has been reported - progressive cortical atrophy and recurrent
  mucosal infections first manifesting at 34 - in a single patient (PMID:32874693). It is not
  curated as a phenotype here because one case cannot establish whether it belongs to the
  syndrome, and the report itself speculates about the gene involved rather than demonstrating
  it. Recorded so the next curator knows it was seen and set aside deliberately.

📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Chromosome 3q29 Microduplication Syndrome · 2026-09-03T19:20:38Z · View source

De novo curation of the 3q29 reciprocal duplication from primary literature plus one openscientist deep-research run. The minimal-critical-region question is curated as a CONTROVERSY carrying both positions with their own evidence (BDH1-alone versus no critical region), and the causal link from the candidate-gene node to the clinical layer is INDIRECT_UNKNOWN_INTERMEDIATES rather than DIRECT because of it. A second INTERPRETATION discussion records which 3q29 findings do and do not transfer from the reciprocal deletion, since the schizophrenia association that dominates the 3q29 literature is deletion-only. Three reference_title values were initially written from memory and corrected against the cache after the validator flagged them. Validated: schema, terms, 33/33 snippets, entity refs, causal targets, duplicate keys, enum values, qualifier terms.

OpenScientist ▸

1. Disease Information

openscientist-autonomous 2026-09-03T19:04:06.868854

1. Disease Information

Overview. Chromosome 3q29 microduplication syndrome is a rare genomic disorder caused by a recurrent copy-number gain of ~1.6 Mb at chromosome band 3q29 (hg19 chr3:~195,700,000–197,350,000). It is the reciprocal of the better-characterized 3q29 microdeletion syndrome. The clinical picture is a variable, generally mild neurodevelopmental disorder: developmental/speech delay, learning disability or mild–moderate intellectual disability, and a range of accessory features (dysmorphism, ocular and cardiac anomalies, micro- or macrocephaly, obesity). Many carriers are only mildly affected and the duplication is often inherited from a similarly mild parent, so it behaves partly as a susceptibility factor rather than a fully penetrant syndrome (PMID 38421086, 33039685, 39739615).

Key identifiers. - MONDO: MONDO:0012761 - OMIM: 611936 (Chromosome 3q29 microduplication syndrome) - Orphanet: ORPHA:284169 (3q29 microduplication syndrome) - ICD-11: LD44 (chromosomal duplication category); ICD-10: Q92.3 (partial trisomy) - Reciprocal disorder: 3q29 microdeletion syndrome — OMIM 609425, Orphanet ORPHA:66634

Synonyms / alternative names: 3q29 duplication syndrome; 3q29 microduplication; trisomy 3q29; dup(3)(q29); 3q29 microduplication syndrome (reciprocal to 3q29 deletion).

Information source type: Disease-level aggregated resources plus published individual case reports; not derived from a single EHR system. A patient registry exists for the reciprocal deletion (3q29deletion.org, PMID 37691301).

2. Etiology

Primary cause — genetic (structural). A recurrent interstitial duplication of ~1.6 Mb at 3q29 containing ~21 protein-coding genes (PMID 37165454). Reported duplications range from ~448 kb to ~2.3 Mb, classically spanning TFRC → BDH1 (PMID 29501613). Origin is non-allelic homologous recombination (NAHR) between flanking segmental duplications (low-copy repeats): in 89% (16/18) of probands breakpoints fell within paralogous 20-kbp segments inside the 3q29 SDs (PMID 37165454).

Genetic risk factors. - The recurrent CNV itself is the causal lesion. - Second-hit CNVs / additional variants act as risk/modifier factors and were frequent in cohorts (PMID 33039685); additional contributory genetic findings were present in 11/46 patients (PMID 38421086). - Local segmental-duplication architecture and haplotype diversity at 3q29 modulate NAHR risk (PMID 37165454).

Environmental risk factors: None established. No toxin, infectious, dietary, or occupational exposure is implicated in causing the CNV. Parental age effects are not established for this locus.

Protective factors: None specifically identified. Reduced penetrance implies protective genetic-background/modifier effects exist but are uncharacterized.

Gene–environment interactions: No specific GxE interaction documented. Variable expressivity is currently best explained by genetic modifiers / second-hit variants (oligogenic model), not by environment (PMID 33039685, 38421086).

3. Phenotypes

Phenotype frequencies are approximate (small cohorts, ascertainment bias toward NDD). Duplication features are consistently less frequent and milder than in the reciprocal deletion (PMID 39739615).

Phenotype	Type	Frequency (indicative)	Onset	Suggested HPO
Speech/language delay	developmental	Common (most frequent)	Childhood	HP:0000750
Global developmental delay	developmental	Common	Infancy/childhood	HP:0001263
Learning disability	cognitive	High (isolated dup)	Childhood	HP:0001328
Intellectual disability (mild–moderate)	cognitive	Lower than in deletion	Childhood	HP:0001249
Microcephaly	physical	~50% of reported patients	Congenital/childhood	HP:0000252
Macrocephaly	physical	Subset	Childhood	HP:0000256
Facial dysmorphism	physical sign	Common	Congenital	HP:0001999 / HP:0000271
Ocular abnormalities	physical	Frequent	Congenital/childhood	HP:0000478
Congenital heart defect	physical	Frequent	Congenital	HP:0001627
Epilepsy/seizures	neurological	Subset	Childhood	HP:0001250
Structural brain anomaly (e.g., gray-matter heterotopia, cortical atrophy)	imaging	Subset	Variable	HP:0002011
Generalized obesity / overweight	metabolic	Subset (mirror trait)	Childhood	HP:0001513
Cleft palate	physical	Uncommon	Congenital	HP:0000175
Musculoskeletal anomalies	physical	Subset	Childhood	HP:0011842
Dental anomalies	physical	Subset	Childhood	HP:0000164
Hypotonia	neurological	Subset	Infancy	HP:0001252
ASD / autistic features	behavioral	Subset	Childhood	HP:0000717
Recurrent infections	immunologic	Reported (case)	Variable	HP:0002719

Phenotype characteristics: onset predominantly congenital-to-childhood; a notable late-onset (age 34) presentation with progressive cortical atrophy and recurrent mucosal infections has been reported (PMID 32874693). Severity is variable/mild; course generally stable (developmental), though brain-atrophy and epilepsy subsets may progress.
Quality-of-life impact: driven mainly by cognitive/learning and speech impairment affecting education and daily functioning; cardiac/ocular anomalies may need intervention. No syndrome-specific EQ-5D/SF-36 data published for the duplication.

Core spectrum quote: "clinical features that include intellectual disability, language delay, epilepsy, structural brain anomalies, micro/macrocephaly, generalized obesity, ocular abnormalities, distinctive facial features, cleft palate, and musculoskeletal anomalies" (PMID 33039685).

Psychiatric distinction (important). Large schizophrenia case-control CNV studies associate the 3q29 deletion — not the duplication — with schizophrenia (PMID 24776740, 22130109). The duplication is instead a recurrent susceptibility locus for autism spectrum disorder and developmental delay (PMID 22900207, 39080272), with schizophrenia and generalized anxiety being phenotypes unique to deletion carriers (PMID 39739615). Counseling should reflect this dosage-direction asymmetry.

4. Genetic / Molecular Information

Causal lesion: recurrent 3q29 duplication (dosage gain), not a point mutation. Variant class: structural — copy-number gain (tandem/interstitial duplication). ACMG/AMP CNV classification: recurrent 1.6-Mb 3q29 duplication is generally VUS to likely pathogenic / pathogenic with reduced penetrance depending on inheritance and second hits; many are inherited from unaffected/mildly affected parents (PMID 38421086).

Genes in the recurrent interval (~21 protein-coding), key candidates: - DLG1 (HGNC:2900; SAP97) — synaptic MAGUK scaffolding protein; strongest candidate (PMID 29501613, 24838842). - BDH1 (HGNC:1027) — mitochondrial 3-hydroxybutyrate dehydrogenase (ketone-body/energy metabolism); smallest single-gene critical region defined (PMID 39739615, 29501613). - PAK2 (HGNC:8591) — p21-activated kinase; cytoskeletal/synaptic signaling (PMID 24838842). - FBXO45 (HGNC:29148) — synaptic ubiquitin-ligase adaptor, neuronal development (PMID 24838842). Full verified gene inventory (Ensembl GRCh37, chr3:195,700,000–197,350,000; 22 protein-coding genes, this analysis): BDH1, CEP19, DLG1, FBXO45, MFI2/MELTF, NCBP2, NRROS/LRRC33, PAK2, PCYT1A, PIGX, PIGZ, RNF168, SENP5, SLC51A/OSTA, SMCO1, TCTEX1D2, TFRC, TM4SF19, UBXN7, WDR53, ZDHHC19 (+1 putative transcript). This matches the literature "~21 genes" (PMID 37165454).

Contiguous-gene / dosage-pleiotropy links (candidate): beyond the neurodevelopmental core (DLG1, PAK2, FBXO45, BDH1), the interval carries genes with independent Mendelian disease relevance that plausibly contribute to the pleiotropic phenotype: CEP19 (recessive morbid obesity / ciliopathy → obesity), PCYT1A (retinal dystrophy with spondylometaphyseal dysplasia → ocular anomalies), RNF168 (RIDDLE-syndrome DNA-damage response → immune/radiosensitivity), TFRC (transferrin receptor; combined immunodeficiency → recurrent infections). These are hypothesized dosage contributors, not proven for the duplication.

Minimal critical region: progressively refined from DLG1+BDH1 (448 kb; PMID 29501613) to BDH1 alone (single-gene duplications associated with ASD, heart defects, biliary tract dysfunction, obesity; PMID 39739615).

Functional consequence: presumed gain-of-dosage (increased gene expression) of dosage-sensitive synaptic/metabolic genes; not loss-of-function.

Allele frequency: rare; the recurrent CNV is essentially absent/very rare in gnomAD-SV controls and enriched in NDD cohorts (~1:5000 among NDD patients; PMID 39739615).

Somatic vs germline: germline; both de novo and inherited (most inherited; PMID 38421086). Post-zygotic occurrence documented as a discordant CNV in monozygotic twins with psychosis (PMID 39080272).

Modifier genes / epigenetics: second-hit CNVs modify severity (PMID 33039685); no locus-specific methylation/histone signature (episignature) is established for the duplication. Chromosomal abnormality: dup(3)(q29), submicroscopic — karyotype normal, detected by microarray.

5. Environmental Information

No environmental, lifestyle, or infectious agent is known to cause or trigger 3q29 microduplication syndrome. It is a constitutional genomic disorder. (Obesity within the phenotype may be modulated by diet/lifestyle as in the general population, but this is not disease-specific.) Infectious agents: not applicable.

6. Mechanism / Pathophysiology

Causal chain (initiating lesion → clinical manifestation):

Segmental duplications flanking 3q29 provide high sequence identity that predisposes to misalignment during meiosis (PMID 37165454).
Misalignment leads to non-allelic homologous recombination (NAHR) between paralogous ~20-kbp SD segments (PMID 37165454).
NAHR results in a recurrent ~1.6-Mb duplication (3 copies) of ~21 genes, transmitted in the germline.
Extra gene copies lead to increased dosage/expression of dosage-sensitive genes — notably DLG1, BDH1, PAK2, FBXO45 (inferred; PMID 29501613, 24838842).
Elevated DLG1/PAK2/FBXO45 dosage is inferred to perturb synapse assembly, glutamatergic scaffolding and neuronal cytoskeletal signaling (inferred from gene function; PMID 24838842).
Elevated BDH1 dosage is inferred to alter ketone-body/mitochondrial energy metabolism, potentially affecting neuronal and biliary function (inferred; PMID 39739615).
Synaptic + metabolic perturbation leads to altered neurodevelopment → developmental/speech delay, learning disability, variable ID, seizures, brain structural anomalies (PMID 33039685, 29501613).
Branch: presence of a second-hit variant/CNV shifts the outcome toward more severe/syndromic disease (e.g., cerebral palsy, severe ID); its absence results in the common mild phenotype (PMID 33039685, 38421086).
Reduced penetrance: in a permissive genetic background the dosage gain may produce no or minimal clinical effect (inherited-from-unaffected-parent scenario; PMID 38421086).

Molecular pathways (candidate): glutamatergic synaptic scaffolding via DLG1/PSD-95 family (MAGUK); PAK2-mediated Rho-GTPase/cytoskeletal signaling; ketone-body metabolism via BDH1. Cellular processes: synapse organization, dendritic/spine development, neuronal migration (heterotopia reported, PMID 29501613). Metabolic changes: possible ketone/energy-metabolism shift via BDH1 (interconverts acetoacetate ↔ D-3-hydroxybutyrate; CHEBI:17968 (R)-3-hydroxybutyrate, CHEBI:13705 acetoacetate), and biliary tract dysfunction (PMID 39739615); SLC51A/OSTA in the interval is a bile-acid transporter, offering a candidate link to the reported biliary phenotype. Immune involvement: recurrent infections in isolated cases (PMID 32874693) — not a core feature.

Model-organism support: direct duplication models are lacking. Deletion Df/+ mice show neurodevelopmental/behavioral abnormalities and reduced paraventricular oxytocin neurons, with social deficits rescued by oxytocin (PMID 35346312) — informative for the locus but reflecting loss, not gain, of dosage.

Suggested ontology terms: GO:0050808 (synapse organization), GO:0007268 (chemical synaptic transmission), GO:0007612/GO:0007611 (learning/memory), GO:0046951 (ketone body biosynthesis); CL:0000540 (neuron), CL:0000679 (glutamatergic neuron).

7. Anatomical Structures Affected

Primary organ/system: central nervous system (UBERON:0001017) — brain (UBERON:0000955); cerebral cortex, lateral ventricles (periventricular heterotopia, PMID 29501613), cortical atrophy (PMID 32874693).
Secondary organ involvement: eye (UBERON:0000970) — ocular anomalies; heart (UBERON:0000948) — congenital heart defects; craniofacial skeleton — dysmorphism, cleft palate (UBERON:0001716 secondary palate); musculoskeletal system; teeth; biliary tract (case-level, PMID 39739615); adipose/metabolic (obesity).
Body systems: nervous, cardiovascular, ocular/visual, musculoskeletal, craniofacial, endocrine/metabolic.
Cell/tissue level: neurons and synapses (nervous tissue) are the principal targets.
Subcellular: postsynaptic density/synapse (GO:0014069), mitochondria (GO:0005739, via BDH1), nucleus.
Lateralization: generally bilateral/symmetric; the reported heterotopia was unilateral (right lateral ventricle, PMID 29501613).

8. Temporal Development

Onset: congenital to early childhood; developmental delay usually recognized in infancy/toddlerhood. A late-onset adult presentation (34 y) is documented (PMID 32874693). Onset pattern: insidious/chronic (developmental).
Progression: developmental features are generally stable over time; most carriers are non-progressive. Subsets show progressive features (cortical atrophy, epilepsy) (PMID 32874693). Duration: lifelong.
Course pattern: static/chronic; not relapsing-remitting.
Critical periods: prenatal/early-childhood neurodevelopment is the key window; several diagnoses were made prenatally by microarray (PMID 33039685), enabling early developmental intervention.

9. Inheritance and Population

Epidemiology: rare; estimated ~1:5000 among patients with a neurodevelopmental phenotype (PMID 39739615). General-population prevalence is not firmly established; only ~60+ patients are described in the literature (16 early cases + 11 [PMID 33039685] + 46-patient cohort [PMID 38421086] + others).
Inheritance pattern: autosomal, dominant with reduced penetrance and variable expressivity; most cases inherited from a mildly affected/unaffected parent, some de novo (PMID 38421086).
Penetrance: incomplete/reduced (PMID 39739615). Expressivity: highly variable (PMID 32874693).
Anticipation: not established. Germline/post-zygotic mosaicism: post-zygotic origin documented in an MZ-twin pair discordant for psychosis (PMID 39080272). Founder effects/consanguinity: not relevant (recurrent NAHR event, not a founder mutation). Carrier frequency: not defined.
Population demographics: no strong ethnic predilection; cohorts from Europe (France, Romania, Italy), North America, China. Sex ratio: roughly balanced/slight male excess in NDD cohorts (~56–62% male in related 3q29 series, PMID 37691301, 35297118). Age distribution: predominantly children at ascertainment.

10. Diagnostics

First-line test: chromosomal microarray analysis (CMA / aCGH / SNP-array) — the diagnostic gold standard; detects the submicroscopic ~1.6-Mb gain (PMID 33039685, 32874693). Karyotype is normal (lesion below cytogenetic resolution).
Confirmation/segregation: qPCR and FISH; parental testing to assess inheritance (PMID 39739615).
Sequencing: WES/WGS recommended when presentation is severe or syndromic, to detect modifying second-hit variants (PMID 38421086). Long-read/optical mapping resolves complex SD architecture and breakpoints (research; PMID 37165454).
Prenatal: CMA on chorionic villus/amniocentesis samples — several 3q29 duplications identified prenatally (PMID 33039685).
Adjunct workup by phenotype: brain MRI (heterotopia, atrophy; PMID 29501613, 32874693), echocardiography (CHD), ophthalmologic exam, developmental/cognitive assessment.
Biomarkers: no specific molecular biomarker; diagnosis is genomic.
Differential diagnosis: other recurrent NDD-associated CNVs (16p11.2, 22q11.2, 1q21.1), 3q29 deletion syndrome, and overlapping trisomy 3q / adjacent CNVs (e.g., 1q43q44 overlap, PMID 30263904; OAVS-associated proximal 3q29 dup, PMID 25735547). Co-occurring monogenic disease can confound (e.g., AMeD/ADH5-ALDH2, PMID 41039406).
Screening: not part of newborn screening; cascade testing of relatives is appropriate given frequent inheritance.

11. Outcome / Prognosis

Survival/mortality: the syndrome is not intrinsically life-limiting; no reduced life expectancy documented for isolated duplications. Mortality risk depends on associated anomalies (e.g., severe congenital heart disease).
Morbidity/function: dominated by learning disability, speech/language impairment and variable ID; global adaptive-function deficits are well documented in the reciprocal deletion (PMID 37740553) and, more mildly, expected here. Most isolated-duplication patients have mild NDD (PMID 38421086).
Complications: epilepsy, structural brain anomalies, cardiac and ocular disease, obesity, musculoskeletal issues; psychiatric comorbidity possible but less than in the deletion (schizophrenia/GAD were unique to deletion carriers, PMID 39739615).
Recovery/course: developmental features are stable/chronic; early intervention (speech/OT/PT, special education) improves functional outcome.
Prognostic factors: presence of a second-hit variant and additional structural anomalies predict a more severe outcome (PMID 33039685, 38421086); isolated duplication predicts milder outcome.

12. Treatment

No disease-specific or curative therapy exists; management is symptomatic, multidisciplinary and supportive.

Developmental/behavioral: early intervention — speech therapy, occupational therapy, physical therapy, special education; behavioral support for ASD/ADHD features (NCIT: Rehabilitation Therapy).
Neurologic: standard antiseizure medication for epilepsy (NCIT: Anticonvulsant Agent).
Psychiatric: treat comorbid ADHD/anxiety/psychosis per standard guidelines if present (more relevant to the reciprocal deletion).
Cardiac: surgical/interventional correction of congenital heart defects as indicated (e.g., valvuloplasty) (NCIT: Cardiac Surgery); reciprocal-deletion literature includes balloon valvuloplasty for pulmonary stenosis (PMID 36305444).
Ophthalmologic/orthopedic/dental: treat specific anomalies (strabismus/refractive correction, scoliosis/pectus management, dental care).
Metabolic: weight/obesity management.
Pharmacogenomics / advanced therapeutics (gene, cell, RNA, targeted, immuno): none established or in trials specific to this CNV. Oxytocin rescued social deficits in the deletion mouse model (PMID 35346312) — hypothesis-generating, not a duplication therapy.
Genetic counseling: essential given frequent parental inheritance and reduced penetrance.

13. Prevention

Primary prevention: none possible (constitutional germline CNV). Genetic counseling for recurrence risk (up to ~50% transmission from a carrier parent, though penetrance is reduced) (PMID 38421086).
Reproductive options: prenatal CMA (documented prenatal diagnoses, PMID 33039685) and preimplantation genetic testing for known familial CNV.
Secondary prevention: early developmental screening and intervention; surveillance for treatable anomalies (cardiac, ocular, seizures).
Tertiary prevention: multidisciplinary follow-up to limit complications (educational support, epilepsy control, cardiac monitoring).
Cascade screening of at-risk relatives.
Immunization / public-health / environmental interventions: not applicable to etiology.

14. Other Species / Natural Disease

Taxonomy: Homo sapiens (NCBI:txid9606). No naturally occurring 3q29-duplication disease is described in companion animals or wildlife (OMIA: none specific).
Orthologous genes: the human 3q29 genes have conserved mouse orthologs (Dlg1, Bdh1, Pak2, Fbxo45) enabling engineered models. Evolutionary conservation: synaptic scaffolding (DLG1) and PAK signaling are deeply conserved across vertebrates.
Comparative biology: the syntenic region has been engineered in mouse (deletion Df/+; PMID 35346312). Zoonotic potential / transmission: not applicable.

15. Model Organisms

Available models: mouse is the principal system. A 3q29 deletion mouse (Df/+) recapitulates neurodevelopmental/behavioral abnormalities with high construct and face validity and shows reduced hypothalamic oxytocin neurons (PMID 35346312). A dedicated duplication (gain-of-dosage) mouse model is, to the best of current literature, lacking — a key gap.
Model types: engineered chromosomal-region models (deletion); single-gene transgenic/knock-in models of DLG1, PAK2, BDH1 exist in general neuroscience literature and could serve as candidate-gene overexpression models.
Phenotype recapitulation: deletion Df/+ mice reproduce social/behavioral deficits (face validity) but model the opposite dosage direction to the duplication; caution in interpretation.
Applications: dissecting synaptic and oxytocinergic mechanisms; testing candidate interventions (e.g., oxytocin, PMID 35346312).
Resources: MGI (mouse orthologs Dlg1, Bdh1, Pak2, Fbxo45); IMPC/IMSR for single-gene alleles.

Key References (PMID)

33039685 — Coyan & Dyer 2020: 11 new cases + literature; second-hit modifiers; prenatal cases.
38421086 — Massier et al. 2024: cohort of 46 patients; mild inherited NDD; SRO uncertain.
39739615 — Kashevarova et al. 2025: review + BDH1 single-gene critical region; dup vs del comparison; 1:5000.
29501613 — Tassano et al. 2018: 448-kb DLG1+BDH1 critical region; heterotopia.
24838842 — Fernández-Jaén et al. 2014: severe case; PAK2/DLG1/BDH1/FBXO45 candidates.
32874693 — Streata et al. 2020: phenotype heterogeneity; late-onset case.
37165454 — Yilmaz et al. 2023: NAHR mechanism, segmental duplications, 21 genes.
30263904 — Kessi et al. 2018: overlapping CNV case.
25735547 — Guida et al. 2015: proximal 3q29 dup with OAVS.
39080272 — Ormond et al. 2024: post-zygotic 3q29 dup in MZ twins.
41039406 — 2025: 3q29 dup co-occurring with AMeD (ADH5/ALDH2) syndrome.
35346312 — Takemoto et al. 2022: 3q29 deletion mouse; oxytocin rescue.
36305444 — Kaba & Çelik 2022: reciprocal 3q29 deletion case (diagnostic/differential context).
37691301 — Pollak et al. 2023: 3q29 registry/musculoskeletal (deletion; registry context).
24776740 — Szatkiewicz et al. 2014: Swedish schizophrenia CNV study; 3q29 deletion associated with SCZ.
22130109 — Grozeva et al. 2012: UK WTCCC CNV frequencies; 3q29 deletion enriched in SCZ.
22900207 — Nomura & Takumi 2012: review of CNV-based psychiatric animal models; 3q29 among ASD/SCZ loci.
Ensembl GRCh37 REST (computational, this analysis): 22 protein-coding genes in chr3:195.70–197.35 Mb.

Limitations & Future Directions

Evidence is dominated by case reports/small cohorts; frequencies are indicative and ascertainment-biased toward NDD.
The smallest region of overlap and the true driver gene(s) remain unresolved (BDH1 vs DLG1 debated).
No duplication-specific animal model, no episignature, and no locus-specific therapy exist.
Priorities: large genotype–phenotype registries for the duplication, dosage-gain mouse/organoid models, functional dissection of DLG1/BDH1 overexpression, and quantification of penetrance/recurrence risk for counseling.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	17
Resolved	17
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	17
On topic	16
Off topic	0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	42
Resolved	36
Unresolved (possible confabulation)	0
Obsolete	0
Unverifiable	6
Terms whose name was checked	26
Terms named correctly	4
Terms named as a different term	16
Terms whose name is worth a second look	6

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

HP:0000750 (1 mention) - the report calls it "Childhood"; HP calls it Delayed speech and language development
HP:0001328 (1 mention) - the report calls it "Childhood"; HP calls it Specific learning disability
HP:0001249 (1 mention) - the report calls it "Childhood"; HP calls it Intellectual disability
HP:0000252 (1 mention) - the report calls it "Congenital/childhood"; HP calls it Microcephaly
HP:0000256 (1 mention) - the report calls it "Childhood"; HP calls it Macrocephaly
HP:0000478 (1 mention) - the report calls it "Congenital/childhood"; HP calls it Abnormality of the eye
HP:0001250 (1 mention) - the report calls it "Childhood"; HP calls it Seizure
HP:0002011 (1 mention) - the report calls it "Variable"; HP calls it Morphological central nervous system abnormality
HP:0001513 (1 mention) - the report calls it "Childhood"; HP calls it Obesity
HP:0000175 (1 mention) - the report calls it "Congenital"; HP calls it Cleft palate
HP:0011842 (1 mention) - the report calls it "Childhood"; HP calls it Abnormal skeletal morphology
HP:0000164 (1 mention) - the report calls it "Childhood"; HP calls it Abnormality of the dentition
HP:0001252 (1 mention) - the report calls it "Infancy"; HP calls it Hypotonia
HP:0000717 (1 mention) - the report calls it "Childhood"; HP calls it Autism
HP:0002719 (1 mention) - the report calls it "Variable"; HP calls it Recurrent infections
UBERON:0000970 (1 mention) - the report calls it "Secondary organ involvement: eye"; UBERON calls it eye**

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

HP:0001263 (1 mention) - the report calls it "Infancy/childhood"; HP calls it Global developmental delay, and lists "Developmental delay in early childhood" among its other names
HP:0001627 (1 mention) - the report calls it "Congenital"; HP calls it Abnormal heart morphology, and lists "Congenital heart defect" among its other names
GO:0007611 (1 mention) - the report calls it "learning/memory"; GO calls it learning or memory
GO:0046951 (1 mention) - the report calls it "ketone body biosynthesis"; GO calls it ketone body biosynthetic process, and lists "ketone body biosynthesis" among its other names
UBERON:0001017 (1 mention) - the report calls it "Primary organ/system: central nervous system"; UBERON calls it central nervous system**
GO:0014069 (1 mention) - the report calls it "Subcellular: postsynaptic density/synapse"; GO calls it postsynaptic density**

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

Chromosome 3q29 Microduplication Syndrome

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Diagnosis

Prevalence

Source YAML

References & Deep Research

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Key References (PMID)

Limitations & Future Directions

Artifacts

Reference Validation

Term Validation

Terms the report names something else

Terms whose name is worth a second look

Prefixes with no resolver